Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Antiplatelet therapy beyond 2012: role of personalized medicine.

Tantry US, Budaj A, Gurbel PA.

Pol Arch Med Wewn. 2012;122(6):298-305. Review.

2.

[Myocardial infarction: Role of new antiplatelet agents].

Silvain J, Bellemain A, Ecollan P, Montalescot G, Collet JP.

Presse Med. 2011 Jun;40(6):615-24. doi: 10.1016/j.lpm.2011.03.002. Epub 2011 Apr 20. Review. French.

PMID:
21511430
3.

New antiplatelet agents in the treatment of acute coronary syndromes.

Sabouret P, Taiel-Sartral M.

Arch Cardiovasc Dis. 2014 Mar;107(3):178-87. doi: 10.1016/j.acvd.2014.01.009. Epub 2014 Mar 11. Review.

4.

Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Capranzano P, Mehran R, Tamburino C, Stone GW, Dangas G.

Hosp Pract (1995). 2010 Nov;38(4):38-43. doi: 10.3810/hp.2010.11.338.

PMID:
21068525
5.

Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.

Coleman CI, Limone BL.

Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.

PMID:
23631863
6.

Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.

Jeong YH, Tantry US, Gurbel PA.

Expert Opin Pharmacother. 2012 Aug;13(12):1771-96. doi: 10.1517/14656566.2012.704909. Epub 2012 Jul 12. Review.

PMID:
22783896
7.

[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].

Koziński M, Grześk G, Kubica J.

Kardiol Pol. 2012;70(2):206-12. Polish. No abstract available.

PMID:
22427098
8.

"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?

Kern MJ.

Catheter Cardiovasc Interv. 2012 Feb 1;79(2):255-62. doi: 10.1002/ccd.24299. No abstract available.

PMID:
22271555
9.

Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.

Orban M, Riegger J, Joner M, Tada T, Okrojek R, Hausleiter J, Kastrati A, Massberg S, Sibbing D.

Platelets. 2012;23(5):395-8. doi: 10.3109/09537104.2012.691189. Epub 2012 Jun 6. Erratum in: Platelets. 2012;23(5):398.

PMID:
22671583
10.

Clopidogrel in coronary artery disease: update 2012.

Huber K.

Adv Cardiol. 2012;47:31-8. doi: 10.1159/000338051. Epub 2012 Aug 9. Review.

PMID:
22906901
11.
12.

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M.

Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Review.

14.

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

Wang WE, Wang H, Wang X, Zeng C.

J Thromb Thrombolysis. 2014;37(2):102-6. doi: 10.1007/s11239-013-0918-8. Review.

PMID:
23584598
15.

Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.

Serebruany VL, DiNicolantonio JJ.

Thromb Haemost. 2013 Jul;110(1):5-10. doi: 10.1160/TH13-02-0142. Epub 2013 Jun 7.

PMID:
23743577
16.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
18.

[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].

Grajek S.

Kardiol Pol. 2012;70(2):213-4. Polish. No abstract available.

PMID:
22427099
19.

New anti-platelet agents: the end of resistance?

Kastrati A.

Thromb Res. 2012 Oct;130 Suppl 1:S53-5. doi: 10.1016/j.thromres.2012.08.275. Review.

PMID:
23026663
20.

Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.

Floyd CN, Passacquale G, Ferro A.

Clin Pharmacokinet. 2012 Jul 1;51(7):429-42. doi: 10.2165/11630740-000000000-00000. Review.

PMID:
22568693
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk